Ravulizumab in Pregnancy Shows No New Safety Signals in Global Analysis
A global pharmacovigilance analysis of 354 pregnancies found no unexpected safety signals with the complement inhibitor ravulizumab, with outcomes consistent ...
A global pharmacovigilance analysis of 354 pregnancies found no unexpected safety signals with the complement inhibitor ravulizumab, with outcomes consistent ...
A multicenter Chinese study of 54 patients found that the oral factor B inhibitor iptacopan achieved sustained hemolysis control, near-normal ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine